Treatment With Inclisiran During Peritoneal Dialysis

Background: Inclisiran is a small interfering RNA that prevents PCSK9 (proprotein convertase subtilisin/kexin type 9) synthesis, lowering low-density lipoprotein cholesterol. In ORION trials, efficacy and safety outcomes of inclisiran were similar among different renal impairment degrees, but no data are available in peritoneal dialysis (PD). Case Summary: We present the case of a 47-year-old woman with severe and recurrent cardiovascular disease and end-stage renal disease on PD. Following inclisiran injection, low-density lipoprotein cholesterol levels significantly decreased by 56.2% at 3 months. Reductions in apolipoprotein B, lipoprotein(a), and PCSK9 concentration were observed. No side effects were reported. Discussion: This report suggests, for the first time, that inclisiran may represent a potential treatment option for lipid control in patients undergoing PD, with results comparable to those reported in clinical trials and a good tolerability profile. Take-Home Message: Inclisiran is a potential lipid-lowering therapy in patients on peritoneal dialysis.